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Network modulation following sham surgery
in Parkinson’s disease
Ji Hyun Ko,1 Andrew Feigin,1 Paul J. Mattis,1 Chris C. Tang,1 Yilong Ma,1 Vijay Dhawan,1 Matthew J. During,2
Michael G. Kaplitt,3 and David Eidelberg1
Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA. 2Department of Molecular Virology, Immunology and Molecular Genetics, The Ohio State University,

1

Columbus, Ohio, USA. 3Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA.

Patient responses to placebo and sham effects are a major obstacle to the development of therapies for brain disorders,
including Parkinson’s disease (PD). Here, we used functional brain imaging and network analysis to study the circuitry
underlying placebo effects in PD subjects randomized to sham surgery as part of a double-blind gene therapy trial. Metabolic
imaging was performed prior to randomization, then again at 6 and 12 months after sham surgery. In this cohort, the sham
response was associated with the expression of a distinct cerebello-limbic circuit. The expression of this network increased
consistently in patients blinded to treatment and correlated with independent clinical ratings. Once patients were unblinded,
network expression declined toward baseline levels. Analogous network alterations were not seen with open-label levodopa
treatment or during disease progression. Furthermore, sham outcomes in blinded patients correlated with baseline network
expression, suggesting the potential use of this quantitative measure to identify “sham-susceptible” subjects before
randomization. Indeed, Monte Carlo simulations revealed that a priori exclusion of such individuals substantially lowers the
number of randomized participants needed to demonstrate treatment efficacy. Individualized subject selection based on a
predetermined network criterion may therefore limit the need for sham interventions in future clinical trials.

Introduction

Placebo effects pose a major challenge in the development of
new treatments for neurodegenerative disorders. Parkinson’s
disease (PD) is a case in point. Prominent placebo (or shamsurgical) responses are frequently encountered in trials of new
treatments for this disorder (1, 2). The appreciable size of these
effects has played no small part in the recent failure of several
blinded, early-phase studies of novel interventions for refractory
PD motor symptoms (3).
The neural mechanisms underlying the placebo effect are not
fully understood. In PD subjects, short-term placebo responses
have been associated with ventral striatal dopamine release (refs.
4, 5, and see ref. 6 for review). Indeed, the likely effects of these
changes on effector pathways have been demonstrated through
intraoperative recordings conducted in PD patients undergoing
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deep brain stimulation surgery (7). In these studies, short-term
placebo responses were associated with changes in neural activity
recorded at the subthalamic nucleus (STN) target and also in downstream basal ganglia and thalamic projection zones. Longer-term
placebo responses have been associated, by contrast, with localized imaging changes involving the limbic and paralimbic cortex
and the amygdala (8–10). It is unknown, however, whether these
areas — and perhaps others as well — function in concert to mediate the placebo response as a discrete brain network.
In this study, we used network analysis in conjunction with
brain imaging to identify and validate a specific metabolic topography associated with the response to sham surgery in PD subjects.
Network activity measured under blinded conditions increased
consistently in proportion to the individual sham response; the
changes were reversed by unblinding. In individual subjects,
network activity measured at baseline predicted the subsequent
sham response seen under the blind. This suggested a novel image-based strategy to reduce sham effects in randomized clinical
trials for brain disorders.

Results
Network characterization
Pattern identification. We studied 23 advanced PD subjects (17 men
and 6 women; aged 60.3 ± 1.6 years; disease duration 11.7 ± 1.0
years; baseline off-state motor Unified Parkinson’s Disease Rating Scale [UPDRS] ratings of 39.4 ± 1.8) who were randomized to
sham surgery (SHAM) as part of a 6-month blinded surgical trial
of gene therapy for refractory motor symptoms (Supplemental
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Figure 1. SSRP. Network analysis of metabolic images obtained for 8 PD patients scanned at baseline and again, under the blind, 6 months after SHAM
(see text). (A) The resulting SSRP was characterized by increased metabolic activity in the anterior cingulate cortex (BA 32/24), subgenual cingulate gyrus
(BA 25), inferior temporal cortex, hippocampus, amygdala, and posterior cerebellar vermis. ACC, anterior cingulate cortex; LOB, lobule; SubCAL, subcallosal
gyrus. Pattern is displayed as a bootstrap reliability map thresholded at z =|1.64|, 1-tailed P < 0.05; 1,000 iterations. (B) SSRP also included contributions
from the head of the caudate and anterior putamen (top) and from the VA thalamic nucleus. While voxel weights for these clusters significantly contributed to this network (Table 1), these loadings did not meet the prespecified bootstrap reliability criteria (z = 1.575, 1.472, and 1.348 for the 3 regions,
respectively; 1,000 iterations). (C) A significant ordinal trend in SSRP expression (left) was seen in the 8 responders to SHAM who were used to identify
the pattern. Each subject exhibited an increase in network expression under the blind at 6 months (P < 0.01, binomial test). A similar ordinal trend in SSRP
expression under the blind (P < 0.01, binomial test) was evident in the 8 remaining sham responders (middle) who were not used for pattern identification.
An ordinal trend was not observed under the blind (P = 1.0) for the 7 sham nonresponders (right). Three violations were evident in this group, whereas no
violations were present in either SHAMR group.

Figure 1; supplemental material available online with this article;
doi:10.1172/JCI75073DS1). Of the sham-operated subjects, 16
demonstrated a degree of clinical improvement, as represented by
reductions in UPDRS motor ratings of 2 points or more under the
blind at 6 months. They were termed sham “responders” (SHAMR)
(7). The remaining 7 sham-operated subjects exhibited clinical outcomes typical of PD progression, with either no change or a deterioration, as represented by an increase in blinded UPDRS motor
ratings at 6 months. They were termed sham “nonresponders”
(SHAMNR). We used baseline and 6-month scans from 8 randomly
selected SHAMR subjects for network identification. Scans from
the remaining responders and from the nonresponders were used
prospectively for testing (see Methods and Supplemental Figure 1).
Network analysis identified a significant sham-related metabolic covariance pattern (SSRP), which accounted for 4.8% of the
overall variance in the scan data. This network (Figure 1A) was characterized by increased activity involving the anterior cingulate cortex (Brodmann area [BA] 32/24) and subcallosal gyrus (BA 25), the
hippocampus and parahippocampal gyrus, the amygdala, and the
posterior cerebellar vermis (lobule VII/crus II). The voxel weights
on these regions (Table 1) were found to be reliable by bootstrap
estimation (Z > 1.64, P < 0.05 for the inverse coefficient of variation [|ICV|; see Methods]). The SSRP also included less reliable

contributions from the head of the caudate nucleus and anterior
putamen and from the ventral anterior (VA) thalamus (Figure 1B).
SSRP scores (Figure 1C, left), representing pattern expression for
each subject and time point, exhibited a significant ordinal trend
(P < 0.001, permutation test; 1,000 iterations), with increasing network activity following SHAM in each of the derivation subjects.
Pattern validation. SSRP expression values were computed prospectively in the SHAMR testing cohort (i.e., the 8 SHAMR subjects
not used for network identification) and in the 7 SHAMNR subjects.
Network expression in the SHAMR testing set (Figure 1C, middle) increased consistently following SHAM (0 of 8 violations, P = 0.008,
binomial test); we did not observed an analogous ordinal trend (Figure 1C, right) in the nonresponders (3 of 7 violations, P = 1.0).
As part of pattern validation, we tested alternative explanations for the increases in SSRP expression that were seen under the
blind. First, we considered the possibility that the observed network
changes resulted not from the sham effect, but from the motor improvement that characterized each of the sham responders. If so,
consistent increases in SSRP expression should be evident in subjects
demonstrating comparable clinical improvement under unblinded
(“open-label”) conditions. We therefore measured SSRP expression
in a separate group of 9 PD subjects (Figure 2A, right) scanned in the
off-medication baseline state and again during an open-label levojci.org   Volume 124   Number 8   August 2014
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Network correlation with the sham
response
CoordinatesA
The SSRP changes observed 6 months
Region
BA
x
y
z
ZmaxB
after SHAM (Figure 2B) correlated with
concurrent clinical motor ratings meaIncreased activity
sured under the blind (n = 23: r = –0.749,
Cerebellum (vermis, lobule VII/crus II)
Bilateral
2
–82
–28
3.37
Subcallosal gyrus
25
Left
–2
10
–16
2.83
P < 0.001, Pearson’s correlation). SignifiAnterior cingulate cortex
32/24
Bilateral
–2
32
–2
3.95
cant correlations were present in both
Inferior temporal (fusiform/
37
Right
44
–56
–8
4.44
groups of SHAMR subjects (identifica  parahippocampal gyrus)
19/37
Left
–30
–46
–22
3.03
tion, n = 8: r = –0.774, P = 0.024; testing,
Amygdala
Left
–32
–2
–16
2.08
n = 8: r = –0.780, P = 0.022), but not in the
Hippocampus
Right
22
–14
–12
3.43
SHAMNR group (testing, n = 7: r = –0.213,
Left
–20
–12
–12
2.40
P = 0.646). Of note, baseline (before ranCaudate (head, ventral)
Left
–8
18
–2
2.59
domization) SSRP values (Figure 3A) preThalamus (VA)
Right
10
–4
8
2.31
dicted blinded motor outcomes 6 months
Decreased activity
after SHAM (r = –0.459, P = 0.028). That
Occipital/temporal
19/39
Right
52
–76
8
–2.67
said, motor outcomes following SHAM
Cuneus
18/19
Right
6
–82
30
–2.63
correlated more closely with the actual
Parahippocampal
37
Right
24
–40
–8
–3.85
changes in network expression that were
A
MNI standard space (50). BValues at peak voxel for each region thresholded at Z = ±1.96, P = 0.05.
recorded under the blind. Indeed, the
Regions in which voxel weights were found to be reliable by bootstrap estimation are in bold (|ICV|>1.64,
latter correlation remained significant
P < 0.05; 1,000 iterations).
even after adjusting for differences in
baseline network expression (r = –0.670,
P = 0.001, partial correlation).
Changes in SSRP expression under the blind also correlated
dopa infusion. Treatment outcomes in these subjects were titrated
(r = –0.428, P = 0.041) with concurrent depression ratings according
to be similar to those observed in the SHAMR testing group (see
to the Beck Depression Inventory (BDI). However, mean depresMethods). The network data from these individuals (Supplemental
sion ratings were not influenced by SHAM in the group as a whole
Figure 2A) indicated that while clinically effective, unblinded levo(P = 0.471, paired Student’s t test), or in either set of SHAMR subjects
dopa treatment was not associated with consistent changes in SSRP
expression (5 of 9 violations, P = 1.0, binomial test). Indeed, we ob(P > 0.1). Nonetheless, the correlation between changes in BDI ratserved a significant difference in network modulation (Figure 2A,
ings and network expression was not significant after adjusting for
light gray bars) across the 3 testing sets [F(2,21) = 4.156, P = 0.030],
subject differences in motor outcome (r = 0.330, P = 0.133, partial
with increased expression under the blind in sham responders relacorrelation). We found that the correlation between the changes in
tive to that seen in sham nonresponders (P = 0.014, post-hoc least
SSRP expression and motor ratings persisted, however, after adjustsignificant difference [LSD] test) as well as in responders to open- ing for BDI differences (r = –0.722, P < 0.001, partial correlation).
label levodopa treatment (P = 0.036).
Cognitive performance under the blind (Supplemental Table 2) was
We also considered the possibility that the observed SSRP
not altered by SHAM (P > 0.1, paired Student’s t tests); these meaincreases reflected underlying disease progression (“natural hissures did not correlate with the network changes that we observed.
tory”) effects. To this end, we measured SSRP expression in an
Nodal correlates. We also examined the changes in local metaindependent group of PD subjects (n = 15) who underwent serial
bolic activity that occurred in SSRP nodal regions under the blind
metabolic imaging over a 2-year period (see Methods). We found
(see Methods). Following SHAM, we observed significant regional
that SSRP expression in these individuals (Supplemental Figure 2B)
increases in the anterior cingulate cortex (BA 32/24; P = 0.015,
did not change with advancing disease (8 of 15 violations, P = 1.0,
paired Student’s t test) and in the posterior cerebellar vermis (lobbinomial test). In this vein, we compared blinded SSRP scores in
ule VII/crus II; P = 0.035). Metabolic changes at the cerebellar
the SHAMR and SHAMNR testing sets with parallel changes in the
node correlated with motor outcomes under the blind (r = –0.460,
P = 0.031, partial correlation adjusting for whole-brain activity).
expression of the PD-related metabolic pattern (PDRP) (11–13), a
Changes at the other network nodes following SHAM, as well as
topographically independent metabolic brain network associated
baseline measurements, did not correlate with motor outcomes
with disease progression. Indeed, the subjects exhibited a signifiunder the blind (P > 0.15). Nodal correlations with changes in
cant difference in the trajectories of the 2 networks over time under
BDI ratings and cognitive test measures were also not significant
the blind [F(1,16) = 6.966, P = 0.018, group × network interaction,
(P > 0.10, Pearson’s correlations).
2 × 2 repeated-measures ANOVA (RMANOVA)]. While SSRP expression increased in the sham responders relative to that in the
nonresponders (P = 0.016, post-hoc LSD test), we did not observe a
Network changes following gene therapy
corresponding group difference in PDRP expression (P = 0.216) in
In the blinded surgical trial (Supplemental Figure 1), 21 parthe same subjects. In aggregate, these data show that the observed
ticipants were randomized to STN gene therapy; adenoassociSSRP changes are unlikely to have resulted from intercurrent treatated viral vector-glutamic acid decarboxylase (AAV-GAD) was
ment or disease progression effects.
successfully delivered at the target site in 16 of these subjects.

Table 1. Regions contributing to the SSRP
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Figure 2. Network changes: relationship to the sham response. (A) A significant difference in UPDRS motor outcomes (dark gray bars) was evident across
the 3 testing groups [(F(2,21) = 20.095, P < 0.001, ANOVA]. As expected, motor improvement was similar for the sham responders in the testing set and for
the subjects who received open-label levodopa treatment (P = 0.730, post-hoc LSD); these changes differed from those seen in the sham nonresponders
(P < 0.001). Significant differences were also seen for network activity measurements (light gray bars) in the 3 groups [F(2,21) = 4.156, P = 0.030]. In
contrast to the motor changes, SSRP modulation was greater in the sham responders than in either the sham nonresponders (P = 0.014) or the individuals
receiving open-label levodopa treatment (P = 0.036). (B) A significant correlation was observed between changes in SSRP expression in the SHAM cohort
(n = 23) and concurrent motor outcomes under the blind at 6 months (r = –0.749, P < 0.001, Pearson’s correlation).

Members of this group were classified as responders or nonresponders based on the same clinical ratings criterion that was
used to categorize the sham-operated participants. Accordingly,
14 of the gene therapy subjects were classified as “responders”
(GADR); the 2 gene therapy subjects were classified as “non
responders” (GADNR). We found that blinded motor outcomes
at 6 months (Figure 4, dark gray bars) were similar for the 2
responder groups (change from baseline: SHAMR –7.88 ± 1.20
points; GADR –10.00 ± 1.28 points; P = 0.235, Student’s t test).
Nonetheless, the degree of concurrent network modulation observed under the blind (Figure 4, light gray bars) was larger in
the sham group (P = 0.002). Whereas changes in SSRP expression under the blind correlated with individual motor outcomes
in sham responders (r = –0.638, P = 0.008, Pearson’s correla-

tion), an analogous correlation was not present in GADR subjects (r = –0.125, P = 0.670). Moreover, in contrast to SHAM, no
correlation was present (r = 0.053, P = 0.845) between baseline
SSRP values and blinded 6-month changes in UPDRS motor ratings after STN AAV-GAD gene therapy. These findings point to
the specificity of the SSRP network for the sham response.
Reversal of network changes by unblinding
Last, the functional relationship between SSRP expression and
the sham response was demonstrated by unblinding. In this
study, treatment status was revealed only after the last subject
completed 6 months of blinded follow-up. Because enrollment
took place continuously over nearly 1 year, a number of the
early subjects completed 12 months of postoperative follow-up,

Figure 3. Clinical outcome under the blind correlates with baseline network expression. (A) Baseline SSRP expression in the SHAM subjects (n = 23) correlated
with motor outcome under the blind at 6 months (r = 0.459, P = 0.028, Pearson’s correlation). (B) Accordingly, baseline SSRP expression was lower [t(21) = 3.96,
P = 0.001] in the SHAMR subjects as compared with that in the SHAMNR subjects. Baseline network values were similar [t(37) = 0.113, P = 0.910] for the subjects
who subsequently received gene therapy and for those who received SHAM (see text). The middle lines, boxes, and whiskers represent the median, lower and
upper quartiles, and range, respectively. (C) Monte Carlo simulations were performed to estimate the sample size needed to detect a group difference in motor
outcome based on the data obtained under the blind in the STN AAV-GAD trial (ref. 24, and see Methods). The results of 10,000 random trials are depicted for
simulations of varying sample size for the 2 groups. The simulations indicated that at least 192 randomized subjects were needed to detect a significant group
difference (P = 0.05, 2-tailed Student’s t test) in 95% of the trials. Nonetheless, the number of participants needed to demonstrate the same treatment effect
fell to 84 by a priori exclusion of subjects with baseline SSRP expression below the prespecified criterion. For this analysis, we chose the median baseline SSRP
expression in sham responders (–0.75; dashed lines in A and B). Participants with baseline SSRP values below this criterion exhibited more pronounced sham
responses. Therefore, excluding all such sham-susceptible individuals before randomization lowered the required number of sham surgeries by greater than 50%.
jci.org   Volume 124   Number 8   August 2014
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Figure 4. Effects of treatment on network modulation under the blind.
Changes in SSRP expression (light gray bars) were computed under the
blind at 6 months in the 16 sham responders and 14 STN AAV-GAD gene
therapy responders (see text). Concurrent changes in UPDRS motor scores
(dark gray bars) are presented for comparison. Motor outcomes under the
blind did not differ for the GADR and SHAMR subjects [t(28) = 1.213,
P = 0.235]. Nonetheless, a significant difference in SSRP modulation
was observed in the 2 groups [t(28) = 3.379, P = 0.002].

including 12 months of imaging, while still under the blind
(see Methods). In total, the scans performed at 12 months on
11 SHAMR and 6 GADR subjects were acquired after unblinding
(mean interval between unblinding and scan = 14.7 ± 1.4 weeks).
We found that unblinding had significantly different network
effects in the 2 groups [group × time interaction: F(1,15) = 6.90,
P = 0.019, RMANOVA]. In the SHAMR subjects (Figure 5A),
unblinding resulted in a significant decline in SSRP expression
(P = 0.031, post-hoc LSD test) that was not observed in their
GADR counterparts (P = 0.152).
Analysis of SSRP trajectories from the individual SHAMR subjects (Figure 5B, left) revealed that in the majority (8 of 11 = 72.7%),
unblinding was followed by a decline in baseline-corrected net-

work activity. In 9 (81.8%) of these subjects, unblinded network
expression measured at 12 months was in the range of open-label
values (Figure 5B, dashed lines) determined independently in a
separate PD cohort (Supplemental Figure 2B) scanned under unblinded conditions. This contrasted with SSRP trajectories from
the remaining sham responders who were still under the blind
at 12 months. The time course of network expression (Figure
5B, right) varied considerably in these individuals. Nonetheless,
in each of these cases, network expression measured under the
blind at 12 months was above baseline, exceeding open-label
reference values. Analogous network changes were infrequently
seen in GADR subjects (Figure 5C), whether under blinded or unblinded conditions.

Figure 5. Effects of unblinding on network expression. (A) Eleven sham (SHAMR) and 6 gene therapy (GADR) responders were rescanned at 12 months
after unblinding (see text). The time course of SSRP expression differed for the 2 groups [F(1,15) = 6.900, P = 0.019, group × time interaction, RMANOVA].
Unblinding was associated with a significant decline in network expression in the sham-operated subjects (P = 0.031, LSD test) but not in their gene therapy counterparts (P = 0.152). Outliers (greater than the mean +1.5 × SD) are shown by white circles. (B) After unblinding, the majority of SHAMR subjects
(8 of 11 = 72.7%) exhibited a decline in network expression (left), with values falling in the range (dashed line) seen over a comparable time interval in an
unblinded disease progression cohort (see text). By contrast, SSRP expression remained above this level (right) in the 4 SHAMR subjects who were still
under the blind at 12 months. Dashed line represents 1.5 SD above the mean change in SSRP expression observed in an independent cohort composed of
15 PD subjects scanned twice over a 2-year period (see Supplemental Figure 2B). (C) Six of the 13 gene therapy responders (GADR) who underwent repeat
metabolic imaging at 12 months were unblinded prior to the final imaging session. Unblinding had no significant effect on SSRP expression in these
subjects. Indeed, in 5 of the unblinded GADR subjects (left), network activity at 12 months was in the open-label progression range (dashed line). Similar
network values were observed (right) for the GADR subjects who remained under the blind at the final imaging time point.
3660
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Figure 6. PDRP expression and natural history. (A) The previously characterized PDRP (11, 13, 49). This network is associated with increased (red) pallidal,
thalamic, cerebellar, and motor cortical metabolic activity, with relative reductions (blue) in the lateral premotor and parieto-occipital regions. The displayed
voxel loadings on the pattern were shown to be reliable (P < 0.001) by bootstrap estimation. (B) Voxel-wise correlation of standardized regional loadings on
the SSRP and PDRP topographies exhibited no spatial correspondence between the 2 networks. Less than 0.0001% of the total voxel weight variation was
shared by these patterns (P = 0.957, adjusted for autocorrelation; ref. 42). (C) PDRP expression values computed in the 23 SHAM subjects (right) increased significantly over time (r2 = 0.223, P < 0.001, Bland-Altman correlation). The network progression in this group was continuous (dotted line) with the progression
line (r2 = 0.540, P < 0.001) that was determined independently in 15 subjects (left) with early-stage PD (13). The slope of PDRP progression did not significantly
differ between the early-stage PD subjects (left, b = 0.141; 95% CI: 0.087–0.194) and those who underwent SHAM (right, b = 0.406; 95% CI: 0.175–0.636).

Discussion

The metabolic anatomy of the sham response. In this study, we used
network analysis to identify a specific cerebello-limbic metabolic network associated with the sham response. Network activity increased in sham-operated PD subjects studied under the
blind, correlating to the concurrent changes in clinical ratings.
The network changes observed following SHAM were reversed
by unblinding. Analogous network responses were not evident,
however, during open-label levodopa treatment or following experimental STN gene therapy.
The SSRP represents a distinctive spatial covariance topography. Several regions contributing to this network have previously
been noted to exhibit increases in local activity in response to placebo. For example, changes in metabolic activity in the anterior
cingulate cortex (BA 32/24) and subgenual cingulate gyrus (BA
25) and in the parahippocampal gyrus and amygdala have been reported in subjects receiving placebo treatments as part of blinded
antidepressant trials (8). The relationship of the placebo response
to metabolic activity in the subgenual cingulate gyrus is particularly relevant, given the relationship of the network changes to
concurrent, blinded BDI depression ratings (14). Of note, participants in the current study were not depressed at baseline, and
SHAM was not associated with significant changes in depression
ratings under the blind. Indeed, the correlation we observed following SHAM between the changes in BDI ratings and SSRP ex-

pression was driven predominantly by the motor changes, which
remained significant even after controlling for individual differences in the BDI response.
Sham responses were associated with increased metabolic
activity in additional components of the limbic cortico-striato-
pallido-thalamo-cortical (CSPTC) loop (15), including the amygdala, VA thalamus, and parahippocampal gyrus. Indeed, changes
in these and related brain regions have been found to accompany
placebo effects occurring in the context of emotional processing
(10, 16). Although ventral striatal dopamine release is a key mediator of the acute placebo response in PD (4, 5, 17), the relationship
to the SSRP is unclear. It is tempting to associate this aspect of the
network topography with specific open-loop circuits connecting
the basal ganglia (particularly the ventral striatum) to motor and
nonmotor cortical areas (18, 19). In this context, the SSRP circuit
can be viewed as conveying reward-based signals from the basal
ganglia to both the limbic and motor cortex. Nevertheless, we
found that local metabolic contributions to SSRP activity from
the striatum and thalamus were weaker and less reliable than
the other network regions (Figure 1B, and see Table 1). Caution is
needed in interpreting the role of these regions in mediating the
sham response.
Nodal analysis revealed significant metabolic responses to
SHAM in only 2 network regions: the anterior cingulate cortex
and the posterior cerebellar vermis. We found that correlations
jci.org   Volume 124   Number 8   August 2014

3661

Research article

between blinded motor outcomes and concurrent changes in local metabolic activity were significant only at the cerebellar node.
These findings underscore the relevance of the nonmotor posterior cerebellum to the sham response. This region, which is the
major cerebellar target of afferent projections from the amygdala
and from the paralimbic cingulate and parahippocampal cortex,
has been linked to affective processing in both health and disease
(20). Indeed, the spatial proximity of the cerebellar SSRP node to
the sensorimotor zones of the anterior vermis (lobules V and VI)
(21) is consistent with the motoric specificity of the sham response
in this study. Nonetheless, this particular cerebellar region cannot
be regarded as a general effector of the sham response. Metabolic
increases localized to the cerebellar vermis are a consistent feature of the abnormal network topography of PD, even in the absence of intercurrent tremor (11, 13, 22). It is conceivable that in
PD, disease-related increases in resting activity in the sensorimotor zones of the cerebellum promote susceptibility to sham effects
mediated by adjacent nonmotor cerebellar regions and associated
projection pathways. Moreover, the specific network topography
seen in PD subjects in response to motor sham effects may not
be generalized to other sham responses in the same population.
Indeed, changes in SSRP expression were not seen in PD subjects
randomized to placebo as part of a blinded clinical trial targeting
the cognitive symptoms of the disorder (ref. 23 and see Supplemental Figure 2C for details). Irrespective of the precise effector,
it is likely that changes in functional connectivity involving limbic
and paralimbic projections to subcortical brain regions will be a
common feature of sham-related network organization.
Examination of the individual SSRP trajectories of the subjects (Figure 5, B and C) illustrated the consistently increasing
tendency (ordinal trend) of the network responses that occurred
under the blind — and the reversal of these changes by unblinding.
Indeed, increases in SSRP expression were present under the blind
in all 16 sham responders. In the absence of other causes for the
observed network changes, we attributed the findings to increases
in the activity of expectation-related neural circuits under blinded
conditions. In most cases, the network changes were reversed by
unblinding, with a decline to “open-label” levels when the expectation of benefit was replaced by cognitive acceptance of the true
treatment status. We note, however, that in some subjects, elevations in SSRP activity persisted after unblinding. It is interesting
to consider whether these individuals were either unable or unwilling to acknowledge the sham intervention that they received
under the blind. Further studies may determine, for instance,
whether these subjects constitute a discrete genotypic subset of
sham responders and whether synaptic dopamine concentrations
are sustained at higher levels in these individuals.
We additionally note that analogous changes in SSRP expression were not observed under the blind in the gene therapy
group. Indeed, despite the small differences in motor benefit observed under the blind at 6 months (Figure 4, dark gray bars) in
the 2 responder groups [GADR: ΔUPDRS = –10.00 ± 1.28; SHAMR:
ΔUPDRS = –7.88 ± 1.20; t(28) = 1.21, P = 0.235], significant SSRP
modulation occurred only in the SHAM group (Figure 4, light
gray bars). Thus, the substantial motor benefit we observed in the
GADR subjects (who represented the majority [87.5%] of the gene
therapy participants in whom the viral vector was successfully de3662
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livered to the STN target; ref. 24) was not explained by sham network effects. It is also important to recognize that the STN itself
likely plays an important role in mediating the short-term placebo
response in PD subjects (7). It is therefore conceivable that this
structure, which represents a critical “bridge” between the cerebellum and basal ganglia (19, 25, 26), was functionally altered by
local delivery of the viral vector. This, in turn, may have limited the
dynamic range of SSRP modulation that was possible in the participants who received STN AAV-GAD gene therapy. Given that both
the SHAM and GAD subjects were treated with similar doses of
open-label levodopa/carbidopa under the blind (24), it is unlikely
that the observed group differences in network modulation resulted directly from dopaminergic effects. That said, the possibility of a functional interaction between AAV-GAD and levodopa at
the STN cannot be excluded.
Levodopa has been found to improve PD-related metabolic
changes in key network regions, including the STN (27–29). It is
also conceivable that levodopa alters the expression of other networks associated with this structure, such as the SSRP. However,
the absence of SSRP modulation during open-label levodopa
treatment (Figure 2A) very likely stems from the lack of uncertainty during the trial. A recent study using [11C] raclopride PET
to monitor synaptic dopamine during the placebo response suggested that uncertainty plays a key role in mediating placebo effects (17). When the patients were assured that they were receiving
real treatment (although they were given placebo), no significant
changes were observed in striatal dopamine release. The presence
of robust increases in SSRP expression under the blind in sham
subjects receiving stable open-label levodopa further supports the
role of uncertainty in determining the activity of this network.
Implications for trial design. Despite the limited number of
subjects used to identify the SSRP in our study, it was possible to
confirm the relationship of this network to the sham response by
measuring its expression prospectively in independent testing
datasets. Indeed, increases in pattern expression under the blind
were confirmed in the prospective SHAMR testing set, along with
robust correlations between these changes and clinical outcome.
The reversal of these changes following unblinding provided further support for the posited relationship between the SSRP network and the sham response.
The relatively limited number of randomized subjects in the
current study and the relatively short period of follow-up under
the blind were similar in scale to other recent sham-controlled
phase II surgical trials for neurodegenerative disorders (30–32).
The demonstration of therapeutic efficacy under such conditions
is especially challenging, given the sizable sham effects that are
typically elicited in blinded surgical trials (1, 30–33). This constraint is magnified by the logistical demands imposed by high
subject throughput and the corresponding need for sufficient
quantities of biological materials with which to treat participants
randomized to the actual intervention. Even more concerning are
the ethical issues attendant to randomizing large numbers of subjects to sham procedures that carry risk but confer little benefit to
the participant (2, 3, 34).
The current findings suggest a novel approach to this issue. In
general terms, placebo responses can potentially be reduced by
excluding subjects found empirically to be susceptible to these and
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related sham effects (e.g., ref. 34). Alternatively, sham responders
may be identified before randomization by quantifying the activity
of the SSRP or related sham networks in baseline functional brain
images. In the current study, baseline SSRP values (Figure 3A)
correlated with blinded motor outcomes 6 months after SHAM.
Indeed, baseline SSRP expression was significantly lower (Figure
3B) in responders to SHAM relative to that seen in nonresponders
(P = 0.001, Student’s t test). This suggested that individuals with
low baseline SSRP expression have the capacity to deploy the network in response to SHAM, with concomitant clinical improvement. This capacity is not present, however, in individuals with
high baseline SSRP expression. These subjects cannot deploy the
network further and are thus unable to generate a meaningful clinical response to the sham intervention.
Based on these considerations, we used Monte Carlo simulations to determine the impact of using baseline SSRP measurements for identification of potential sham responders to randomization. The median value for the SHAMR subjects (Figure
3A, dashed line) was chosen as a cutoff; individuals with baseline
expression below this level were considered to be particularly
susceptible to sham effects and were withdrawn from the simulated experiment.
Simulations based on the baseline SSRP values that we observed empirically in the phase II STN AAV-GAD data (Figure 3C)
suggested that 192 subjects would have to be randomized to detect
a significant group difference in motor outcome in 95% of 10,000
trials (P = 0.05, 2-tailed Student’s t test). Nonetheless, the required
sample size falls to 84 subjects by excluding the potentially susceptible participants, i.e., those with baseline network expression at or
below the prespecified cutoff value. In summary, prospectively computed subject scores for the SSRP or for analogous networks identified under the blind in phase II data may be used subsequently at
phase III to detect and potentially exclude sham-responsive participants before randomization. Of note, baseline metabolic imaging
has already been implemented as a measure to identify potential
trial participants with atypical parkinsonian variant conditions (24).
SSRP-related computations can easily be performed on the same
scans to classify subjects according to their relative susceptibility
to major sham effects under trial conditions. Approximately 35% of
the participants would fall into this category, as determined by baseline SSRP expression values. However, excluding them resulted in a
net reduction in sample size of over 56%.

Methods
Study design
Sixty-six patients with advanced PD were screened for eligibility to participate in a randomized, double-blind, SHAM-controlled multicenter
phase II trial of STN AAV-GAD gene therapy for medically refractory
motor symptoms. A flow diagram for the study is presented in Supplemental Figure 1. Prior to randomization, all subjects underwent metabolic brain imaging in the resting state with 18F-fluorodeoxyglucose
(FDG) PET to exclude atypical parkinsonian “look-alike” conditions
that are generally resistant to PD interventions (24, 35). Following this
screening procedure, 45 PD subjects were randomized 1:1 to receive
either STN AAV-GAD gene therapy (n = 22) or SHAM (bilateral burr
hole placement, n = 23); the subjects and investigators were blinded
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to the treatment status for at least 6 months following the procedure;
1 subject in the AAV-GAD arm was unblinded early because of catheter
misplacement. Finally, 5 additional AAV-GAD patients were excluded
from further analysis because of failed viral vector delivery at the STN
target site (see ref. 24 for details).
At baseline, no significant group differences (P > 0.07) were present regarding age, gender, UPDRS motor ratings (36), BDI ratings (37),
or tests of memory and executive functioning assessed according to
the Hopkins Verbal Learning Test (HVLT) (38), Stroop Interference
Test (39), and the Symbol Digit Modality Test (SDMT) (40). The subjects were rescanned under the blind 6 months after surgery (with the
exception of 1 subject in each group) and again at the conclusion of the
study at 12 months. The subjects were simultaneously unblinded after
the final participant completed 6 months of blinded follow-up. The
surgical procedures performed in the trial were staggered over a 1-year
period. Thus, although the majority (16 of 22 [73%] of the SHAM subjects; 11 of 20 [55%] of the GAD subjects) of participants underwent
imaging at 12 months after unblinding [interval 3.1 ± 0.4 months in
SHAM and 3.5 ± 0.4 months in GAD subjects; t(25) = 0.756, P = 0.457 ],
the remaining 6 SHAM and 9 GAD subjects were still under the blind
at this 12-month time point. The details of the surgical and imaging
procedures performed, as well as the outcome of the 6-month blinded
phase of the trial, have been presented previously (24).

Metabolic imaging
All trial participants included in our analysis (Supplemental Figure 1)
underwent FDG PET at baseline and again, under the blind, at the
6-month time point. All but 2 subjects (1 SHAMR and 1 GADR) underwent repeat PET imaging at 12 months. The subjects fasted overnight
before each scanning session. In all subjects and at all time points,
antiparkinsonian medications were withheld for at least 12 hours
before the start of imaging. In the gene therapy trial, participants
were scanned at 1 of 5 imaging centers as detailed elsewhere (24).
The PET tomographs used at each center, the performance features of the corresponding instruments, and the number of patients
scanned on each platform are provided in Supplemental Table 1. In
the test-retest disease progression and levodopa treatment validation cohorts, scanning was conducted in paired imaging sessions
using the GE Advance tomographic system (GE Healthcare) at The
Feinstein Institute for Medical Research.
All subjects were scanned in 3D mode for 10 minutes, beginning 30
minutes after radiotracer injection. Scanning was conducted in an awake
resting state with eyes open in a dimly lit room and with minimal auditory stimulation. In each subject, the scan pairs were spatially aligned
across conditions, warped into the standard Montreal Neurological
Institute (MNI) space, and smoothed with a 10-mm Gaussian filter using
SPM5 software (http://www.fil.ion.ucl.ac.uk/spm/software/spm5/).
Network analysis
Pattern identification. To identify a specific metabolic covariance pattern associated with the motor response to SHAM, we implemented
a within-subject network mapping strategy, termed ordinal trends/
canonical variates analysis (OrT/CVA; ref. 41). This computational
algorithm relies on supervised principal component analysis (PCA)
to identify distinct spatial covariance patterns (metabolic brain networks) with consistent changes in subject expression across experimental conditions (e.g., refs. 42–44). This approach differs from roujci.org   Volume 124   Number 8   August 2014
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tine voxel-wise univariate analysis in that it requires that the pattern
exhibit an ordinal trend (i.e., a consistent change in expression across
conditions at the individual subject level) in the data. Thus, in OrT/
CVA, network activity is required to increase (or decrease) monotonically in all or most of the subjects. As in other forms of spatial
covariance analysis, large-scale networks are described in terms of
the voxel loadings (“region weights”) on each of the relevant principal component (PC) topographies (45). Likewise, the expression of a
given pattern in each scan is quantified by a specific network activity
measure (“subject score”), the PC scalar multiplier for the subject at
each experimental time point.
In OrT/CVA, as in other forms of spatial covariance analysis, the
significance of the resulting topographies is assessed using nonparametric tests (46). In the initial network identification phase of the analysis, a permutation test of the relevant subject scores is performed to confirm that the observed monotonic changes in pattern expression did not
occur by chance. An ordinal trend was considered significant in the derivation set if a consistent change in pattern expression was present for
all (or most) subjects across experimental conditions (P < 0.05, permutation test). Likewise, the reliability of the voxel loadings on the network
topography is assessed using bootstrap resampling procedures (46).
In the current study, a significant SSRP topography was sought
among the linearly independent (orthogonal) PC patterns that
resulted from OrT/CVA analysis of the scans acquired under the blind
at baseline and 6 months following surgery in 8 sham responders. The
following model selection criteria were applied to the individual patterns: (a) the analysis was limited to the first 6 PCs, which typically
account for at least 75% of the subject × region variance (46); (b)
subject scores for these PCs were entered singly and in all possible
combinations into a series of logistic regression models, with time
(before and 6 months after) as the dependent variable and the subject scores for each set of PCs as the independent variables for each
model. The best model was considered to be that with the smallest
Akaike information criterion (AIC) value. The selected PC(s) in this
model were then used in linear combination to identify the spatial
covariance pattern (if any) that exhibited significant ordinal trend in
the data acquired under the blind in the 8 SHAMR derivation subjects.
Once a significant SSRP was identified in these individuals, the presence of an ordinal trend was confirmed by prospectively measuring
expression values for the pattern in the baseline and 6-month scans
of the 8 remaining SHAMR subjects.
To minimize potential confounds stemming from concurrent
effects of disease progression, we restricted the search for a sham-related metabolic network to the portion of the overall derivation space
that is independent of (i.e., orthogonal to) the stereotyped functional
changes that relate specifically to the underlying neurodegenerative
process. In PD, the latter are represented by a distinct disease-related
metabolic covariance pattern known as the PDRP (11, 12, 42). The
PDRP topography is displayed in Figure 6A; the absence of a correlation
between voxel weights on this network and the SSRP is demonstrated in
Figure 6B. Analysis of the longitudinal scan data from the sham-operated subjects (Figure 6C) revealed significant linear increases in PDRP
expression over time [t(44) = 3.55, P = 0.0009, multiple linear regression]. Because of this network-level progression effect, we orthogonalized the scan data to the PDRP before implementing the OrT/CVA
algorithm. In this way, confounds associated with disease progression
were minimized in the search for the SSRP topography.
3664
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Validation studies. SSRP expression values were computed prospectively on an individual scan basis as described elsewhere (11, 45).
Because of the multicenter design of the current study (24, 47), the
scan data were scrutinized for potential bias caused by tomographic
differences across sites. Indeed, no difference in SSRP values was found
for sham-operated subjects scanned under the blind at the 5 imaging
sites [baseline: F(4,18) = 0.920, P = 0.476; 6 months: F(4,18) = 1.216,
P = 0.338, 1-way ANOVA]. That said, global metabolic activity varied
to some degree across the sites [baseline: F(4,18) = 2.592, P = 0.071;
6 months: F(4,18) = 8.058, P = 0.001]. We therefore adjusted for individual differences in global metabolism, while correlating clinical outcomes with changes in local activity in nodal regions (see below).
It was also important to establish that pattern expression was stable in single subjects. SSRP expression, in fact, had excellent test-retest
reliability (intraclass correlation coefficient [ICC]: 0.937, P < 0.001)
when computed prospectively in scans from an independent group of
PD subjects (n = 14) who were studied twice over a 2-month period.
Further validation was provided using metabolic scan data from
independent PD reference samples to: (a) evaluate the test-retest
reproducibility of prospectively computed network expression values.
This was done using scan data from 14 PD subjects who underwent
repeat imaging over a 2-month period (48); (b) assess the impact of
open-label dopaminergic pharmacotherapy on network expression.
This was done using scan data from 9 PD subjects who were studied at
baseline and during an intravenous levodopa infusion (29) titrated to
produce an improvement in motor ratings comparable to those of the
SHAMR testing set; (c) determine the impact of disease progression on
network expression. This was done using longitudinal scan data from
15 PD subjects who were studied at baseline and again 24 months later
(12). Demographic and clinical features of these cohorts are provided
in Supplemental Table 3.

Statistics
Network modulation and clinical correlation under the blind. After validation, SSRP expression values computed in the testing data (i.e., in
the 8 SHAMR subjects not used for pattern derivation, the 7 SHAMNR
subjects, and in the 9 PD subjects who received open-label levodopa
infusion during imaging) were compared across groups using 1-way
ANOVA with post-hoc LSD tests. Regression analysis was used to
determine whether the observed SSRP changes correlated with clinical outcomes under the blind, particularly with regard to concurrent
changes in UPDRS motor ratings, BDI ratings, HVLT, Stroop Interference Test, and SDMT. Group-wise differences and clinical correlations were also evaluated regionally within the major SSRP nodes
(Table 1) using spherical volumes-of-interest (VOI, radius = 6 mm), as
described elsewhere (43).
Network changes under the blind: comparison with gene therapy. We
additionally compared the changes in network expression observed
under the blind in the sham-operated participants with those measured in the 16 subjects who were randomized to gene therapy with
successful delivery of the viral vector to the STN target (Supplemental
Figure 1 and ref. 24). Based on the UPDRS criteria for sham response
described above (7), 14 of these subjects were classified as GADR, and
2 were classified as GADNR.
Network modulation: effects of unblinding. To determine the effect
of unblinding on SSRP expression, we analyzed baseline, 6-month,
and 12-month scan data from the SHAMR and GADR subjects who
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were unblinded between the latter 2 imaging sessions. RMANOVA
was used to assess the time course of SSRP expression in each group
and to identify potential group × time interaction effects in the network activity data. All statistical analyses were performed using SPSS
13.0 for Windows (SPSS Inc.). Results were considered significant for
P < 0.05. Data are presented as the mean ± SEM (bars and error bars,
respectively), unless stated otherwise.
Monte Carlo simulations. We first created a means of identifying a priori sham–susceptible trial participants, i.e., subjects likely to
develop prominent sham effects under the blind. This was done by
determining a prerandomization network criterion using the distribution (mean and SD) of baseline SSRP values that was observed in
the data (see text). This criterion (dashed line in Figure 3, A and B)
was fixed at –0.75, the median value for baseline SSRP expression
observed in sham responders. We noted that the sham responders
with subthreshold baseline values, i.e., the 50% of SHAMR subjects
with low network expression at baseline, had greater improvement
under the blind than did their high-expression counterparts. Based on
these observations, we hypothesized that excluding such individuals
improves the efficiency of randomized treatment studies by reducing
the magnitude and variability of sham effects in trial populations, with
concomitant lowering of sample size.
To test this hypothesis, Monte Carlo simulations were performed with or without excluding sham-susceptible individuals
before randomization to the active GAD-simulated (GADSIM) or
sham-simulated (SHAMSIM) treatment categories. In both models,
we estimated the minimum number of randomized subjects needed
to detect a difference in GAD versus SHAM clinical outcomes equivalent to that for ΔUPDRS in the 6-month blinded phase of the STN
AAV-GAD trial. In each set of simulations, subjects were randomized 1:1 to the SHAMSIM and GADSIM categories. ΔUPDRS of SHAMSIM
was modeled according to the equation: ΔUPDRSSIM = b0 + b1 ×
SSRPSIM + N(0,δ2), where b0 and b1 are the regression coefficients
of the observed ΔUPDRSSHAM = b0 + b1 × SSRPSHAM and N(0,δ2) is
a normal distribution, with a mean of 0 and a SD of δ determined
empirically in a separate set of 10,000 simulations. A least-squares
fit of the ΔUPDRSSIM data was performed to induce the same variance in ΔUPDRSSIM as that observed in the ΔUPDRSSHAM data, and
identical correlation analysis (Pearson’s coefficient) was performed
with baseline SSRP values. ΔUPDRS for GADSIM was simulated independently to have the same mean and SD as those observed empirically for the GAD group.
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